Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review highlights Ritlecitinib as a promising new oral treatment for Alopecia Areata, emphasizing its targeted action and potential efficacy, especially in adults and adolescents, though it notes the need for further real-world effectiveness and long-term safety studies.

This study reported that some pediatric patients with alopecia areata experienced hair regrowth with dupilumab treatment, particularly those with concomitant atopic dermatitis, suggesting dupilumab may be beneficial when traditional therapies fail.

This study reported that most patients with alopecia areata who responded to ritlecitinib treatment by achieving a SALT score ≤20, SALT score ≤10, or improvements in eyebrow and eyelash assessments at Week 24 maintained their responses through Week 48.

Enhancing Tregs can protect against alopecia areata.

This research reported that the FDA approved Litfulo® (ritlecitinib) as the first oral treatment for severe alopecia areata in adolescents over 12 years old, with 23% of treated patients showing significant hair regrowth in clinical trials compared to 1.6% with placebo.

Ritlecitinib works well and is safe for treating alopecia areata.

In this retrospective study of adolescents with recalcitrant cutaneous lupus, lenalidomide treatment resulted in complete or near resolution of skin symptoms within 6 months, while allowing for a reduction in prednisone dosage.

In this case report, two patients with polyautoimmunity and difficult-to-treat lupus erythematosus experienced significant symptom improvement after adding anifrolumab to their regimen, suggesting its potential as an effective add-on therapy for refractory cutaneous symptoms in autoimmune conditions characterized by elevated interferon alpha activity.

This study found that in Asian patients aged 12 and older with alopecia areata and significant hair loss, ritlecitinib showed clinical efficacy in improving hair regrowth and eyebrow and eyelash scores over 48 weeks, with an acceptable safety profile observed throughout.

This study found that baricitinib, a selective Janus kinase inhibitor, led to significantly improved scalp coverage in alopecia areata patients over 36 weeks compared to placebo, though adverse effects like acne and urinary tract infections were reported.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

This study found that NIMP-R14-conjugated nanoparticles, loaded with roflumilast, effectively targeted neutrophils to reduce inflammation and improve symptoms in a mouse model of psoriasiform dermatitis, suggesting potential for targeted therapy in autoimmune skin diseases.

The authors report that a 62-year-old woman with invasive conjunctival squamous cell carcinoma experienced complete remission two years after combining cemiplimab, retinoic acid, and IFNα-2b treatments, highlighting potential utility despite limited availability of IFNα-2b.

In this real-world study, aumolertinib was found to improve patient-reported outcomes and maintain high disease control and objective response rates similar to those reported in the AENEAS trial for advanced NSCLC patients, supporting its use in first-line treatment.

This study describes characteristics and outcomes for adults initiating ritlecitinib for severe alopecia areata, highlighting increased hair regrowth and physician satisfaction with longer treatment durations, despite ongoing psychosocial impacts like embarrassment and anxiety among patients.

This report observed that a patient with alopecia areata, resistant to ritlecitinib, experienced significant recovery after 24 weeks of treatment with upadacitinib, highlighting its potential in treating ritlecitinib-resistant cases and suggesting personalized treatment strategies in managing alopecia areata.

Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

This study found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg for treating severe alopecia areata at Weeks 24 and 52, potentially influencing reimbursement decisions.

In this study, a 68-year-old man with muscle-invasive bladder cancer and renal insufficiency achieved a partial radiological response to neoadjuvant therapy with gemcitabine and Disitamab Vedotin, without significant adverse events, highlighting a potential alternative for cisplatin-ineligible patients.

This study found that liarozole is more effective than cyproterone acetate for improving PSA response and survival in metastatic prostate cancer after first-line endocrine therapy, while maintaining quality of life.

This study found that patients with alopecia areata receiving ritlecitinib showed immune responses to meningococcal and tetanus vaccines, achieving significant antibody levels after vaccination, and no vaccine-related adverse events or disease exacerbations were reported despite a small sample size.

This study reported that ritlecitinib effectively improved hair regrowth in JAK inhibitor-naïve adolescent patients with severe alopecia areata, achieving significant reductions in SALT scores within 24 weeks, but was less effective for patients who had previously been treated with baricitinib.

This study examined monoclonal antibodies LT-1, LT-2, and LT-7, finding they can effectively detect certain antigens on T and B cells involved in various lymphoproliferative diseases, aiding in the diagnosis of both acute and chronic lymphoid neoplasias.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

In this study, ritlecitinib treatment for 12 and 24 weeks downregulated immunity-related genes and upregulated hair keratin genes in patients with alopecia areata, correlating with scalp hair regrowth response.

This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.

In a proof-of-concept study at Xiangya Hospital, the researchers observed that combining tofacitinib with low-dose interleukin-2 helped maintain remission in refractory alopecia areata patients, with three out of four maintaining complete remission for 11–20 months post-treatment and no adverse events reported.

This case study reports a rare instance of pembrolizumab-induced eyelash trichomegaly in a 63-year-old male patient, highlighting the importance for clinicians to be aware of such uncommon adverse effects to manage patient treatment effectively.

In this study, JAK inhibitors like baricitinib and ruxolitinib were found to be more effective and caused fewer discontinuations due to adverse events in adults with alopecia areata compared to therapies like dupilumab and apremilast, highlighting the need for more high-quality comparative trials.